Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
IPH | Paris | EUR | Real-time | |
IPHA | NASDAQ | USD | Real-time | |
IPHYF | OTC Markets | USD | Delayed | |
IPH | TradeGate | EUR | Delayed |
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
Name | Age | Since | Title |
---|---|---|---|
Mailys Ferrere | 59 | 2017 | Member of Supervisory Board |
Gilles Brisson | 72 | 2007 | Independent Member of Supervisory Board |
Irina Staatz-Granzer | 64 | 2009 | Independent Chairwoman of Supervisory Board |
Olivier Martinez | 54 | 2010 | Member of Supervisory Board |
Jean-Yves Blay | 62 | 2017 | Independent Member of Supervisory Board |
Veronique Chabernaud | 63 | 2015 | Independent Member of Supervisory Board |
Miriam Merad | - | 2018 | Chairman of Strategic Advisory Board |
Pascale Boissel | 58 | 2020 | Independent Vice Chairperson of the Supervisory Board |
Mario Sznol | 66 | 2018 | Strategic Advisory Board Member |
Aurelien Marabelle | - | 2018 | Strategic Advisory Board Member |
Sally Louise Bennett | 52 | 2022 | Independent Supervisory Board Member |
Diane J. Mathis | - | 2024 | Strategic Advisory Board |
Katy Rezvani | - | 2024 | Strategic Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review